LEADER 01757nam  2200565   450 
001 9910136528303321
005 20170919032209.0
010   $a1-119-05339-0
010   $a1-119-05332-3
035   $a(CKB)3710000000616152
035   $a(SSID)ssj0001635497
035   $a(PQKBManifestationID)16388496
035   $a(PQKBTitleCode)TC0001635497
035   $a(PQKBWorkID)14857276
035   $a(PQKB)11408512
035   $a(MiAaPQ)EBC4453516
035   $a(DLC)  2015050089
035   $a(PPN)194496759
035   $a(EXLCZ)993710000000616152
100   $a20151215h20162016  uy|            0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aDrug discovery toxicology $efrom target assessment to translational biomarkers /$fedited by Yvonne Will [and three others]
210  1$aHoboken, New Jersey :$cJohn Wiley & Sons, Incorporated,$d[2016]
210  4$dİ2016
215   $a1 online resource (1,048 pages) $cillustrations (some color)
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a1-119-05324-2 
311   $a1-119-05333-1 
320   $aIncludes bibliographical references and index.
606   $aDrugs$xToxicology
606   $aDrugs$xTesting
606   $aToxicity testing
606   $aHigh throughput screening (Drug development)
615  0$aDrugs$xToxicology.
615  0$aDrugs$xTesting.
615  0$aToxicity testing.
615  0$aHigh throughput screening (Drug development)
676   $a615.9/02
702   $aWill$b Yvonne
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910136528303321
996   $aDrug discovery toxicology$92201800
997   $aUNINA